SGLT2 Inhibitors: Cardiorenal Mechanisms How a glucose-lowering drug became a foundational heart and kidney therapy. Diabzen, [S. l.], v. 4, n. 14, p. 28–29, 2026. Disponível em: https://thediabzen.com/index.php/d/article/view/56. Acesso em: 28 jul. 2026.